At the time of writing, Compass Therapeutics Inc [CMPX] stock is trading at $2.24, up 17.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CMPX shares have gain 3.46% over the last week, with a monthly amount drifted -17.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Compass Therapeutics Inc [NASDAQ: CMPX] stock has seen the most recent analyst activity on February 24, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $12. Previously, Piper Sandler started tracking the stock with Overweight rating on February 19, 2025, and set its price target to $12. On December 23, 2024, D. Boral Capital initiated with a Buy rating and assigned a price target of $32 on the stock. Leerink Partners downgraded its rating to a Market Perform and decreased its price target to $4 on November 15, 2024. Ladenburg Thalmann upgraded its rating to a Buy but $5 remained the price target by the analyst firm on September 16, 2024. Jefferies started tracking with a Buy rating for this stock on January 31, 2023, and assigned it a price target of $8. In a note dated January 27, 2023, Stifel initiated an Buy rating and provided a target price of $9 on this stock.
For the past year, the stock price of Compass Therapeutics Inc fluctuated between $0.76 and $4.08. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Compass Therapeutics Inc [NASDAQ: CMPX] shares were valued at $2.24 at the most recent close of the market. An investor can expect a potential return of 123.21% based on the average CMPX price forecast.
Analyzing the CMPX fundamentals
Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -15.01%, Pretax Profit Margin comes in at -12.93%, and Net Profit Margin reading is -12.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.32 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6300 points at the first support level, and at 1.0100 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.5600, and for the 2nd resistance point, it is at 2.8700.
Ratios To Look Out For
It is important to note that Compass Therapeutics Inc [NASDAQ:CMPX] has a current ratio of 14.96. In addition, the Quick Ratio stands at 14.96 and the Cash Ratio stands at 8.3. Considering the valuation of this stock, the price to sales ratio is 364.42, the price to book ratio is 2.47.
